Zinc-dependent proteases and the spread of cancer
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that cut extracellular matrix (ECM) proteins, cell-adhesion molecules and bound signalling factors. In a tumour, this proteolytic activity can help malignant cells breach a basement membrane, cross tissue boundaries and seed a distant organ. Because catalytic zinc occupies the enzyme’s active site, changes in metal availability, redox state or inhibitor binding can alter how strongly the tumour microenvironment is remodelled.
Zinc-containing matrix metalloproteinases therefore connect atomic-level metal chemistry with tissue-scale invasion, angiogenesis and metastatic outgrowth. Their value to applied bioinorganic chemistry lies in opportunities for selective inhibitors, activity-based imaging and biomarker development. The 16th International Symposium on Applied Bioinorganic Chemistry, held in Ioannina, Greece in June 2023 and organised by the University of Ioannina, brought researchers together to examine those links. Australian teams can draw useful lessons from the meeting as they balance fundamental studies with demanding clinical and commercial pipelines.
How MMPs open a path for metastasis
During metastasis, invasion is not simply a matter of tumour cells pushing forward. It requires coordinated changes in collagen-rich stroma, basement membranes and vascular niches. Collagenases such as MT1-MMP (MMP-14), and gelatinases including MMP-2 and MMP-9, cleave matrix components and expose sites that influence migration. Their products can also release or activate growth factors, turning matrix degradation into a signal that supports survival, new blood-vessel formation and continued invasion.
The tumour microenvironment controls this activity. Hypoxia can alter gene expression in cancer cells and stromal fibroblasts, while tumour-associated macrophages can supply proteases and cytokines that reshape the niche. MMPs may create a permissive environment for metastatic outgrowth, yet individual enzymes can have protective roles in some settings; MMP-9, for example, may restrain tumour growth in certain models. Research therefore needs to distinguish enzyme abundance from catalytic activity, localisation and the tissue context in which each protease acts.
Following MMP activity from tissue to clinic
A translational strategy starts with measurements that preserve spatial information. Bulk tumour tissue can conceal a small population of highly active cells, while blood assays provide a different view of shed or circulating protease. Immunohistochemistry, activity-based protease profiling, imaging probes and spatial transcriptomics can connect MMP localisation with collagen turnover, vascularisation and metastatic burden. Zinc chelators and selective MMP inhibitors then test whether an observed change is causal rather than merely correlated.
Biomarker development also depends on well-characterised clinical cohorts. In Australia, university hospitals, public pathology services and regional cancer centres provide access to staged specimens, although distance and fragmented records complicate standardisation. National biobanks and state tissue-collection programs can support validation, while local multidisciplinary teams remain essential for identifying the cellular source of an MMP signal. Records should include medication, prior surgery and disease stage, since each can reshape matrix metalloproteinase expression.
ISABC 2023 connects enzymes, metals and metastasis
The 16th symposium was designed for this kind of cross-disciplinary exchange. Held in Ioannina in June 2023 under the organisation of the University of Ioannina, ISABC 2023 brought together researchers in applied bioinorganic chemistry, cancer biology, imaging and therapeutic development. Work on zinc-dependent proteases could connect understanding of catalytic zinc with tissue-scale observations of invasion and with practical development of inhibitors or diagnostic tools.
Participants could engage through scientific sessions, poster discussions and early-career activities. The programme included young scientist travel awards, poster prizes and scholarships, with application requirements published through the official symposium information. For anyone reviewing how a specialist meeting is run, the Ioannina venue guide explains the University city, its lake landscape and the meeting locations, while helping delegates plan travel through Greece.
Australian priorities for moving MMP research forward
Australian funding is well suited to collaborative projects that pair mechanistic chemistry with biological validation. NHMRC grants support health and medical research, while ARC support funds discovery, imaging and instrumentation; university partnerships often bridge both schemes. The national emphasis on team science suits MMP projects requiring synthetic chemistry, structural biology, pathology and clinical input. Research priorities that resonate with Australian teams include:
- Designing inhibitors that distinguish catalytic MMP activity from total protein abundance.
- Mapping protease localisation across tumour, stroma, immune and vascular compartments.
- Pairing structural studies with spatial imaging and patient-derived specimens.
- Testing redox and zinc handling alongside conventional cell-culture models.
These priorities fit the country’s biotech landscape in Melbourne, Sydney and Brisbane, where research groups often describe translation as moving a result “from the bench to the bedside.” That plainspoken shorthand captures the need for reproducible assays, intellectual-property pathways and trials designed around Australian regulatory and hospital systems. Translation priorities are equally concrete:
- Pairing tissue biomarkers with imaging that can be repeated during treatment.
- Using national trial networks to test whether protease inhibition changes clinical outcomes.
- Coordinating pathology, data governance and patient follow-up across public hospitals.
Travel support can give early-career researchers “a fair go” at international meetings, especially when flights from Sydney or Perth to Europe cost substantial time and money. The young scientist awards associated with ISABC support more than attendance: they can create mentoring links and expose Australian assays to international standards, strengthening later funding applications.
Engage with ISABC 2023 and build lasting collaborations
Keep the collaboration moving by using the symposium’s scientific and participation resources rather than treating the meeting as an isolated event. Read the programme, identify colleagues studying zinc regulation, protease engineering or metastatic niches, and prepare a concise poster that links catalytic mechanism to a biological result. Early-career applicants can review the scholarship and travel-award criteria, while established teams can check whether the abstract and application requirements match their planned contribution.
For registration, accommodation and abstract-related enquiries, Zita Congress & Event Management serves as the official symposium secretariat. Further participation information is available through the symposium information page. Contact the secretariat early to confirm arrangements, especially when coordinating travel from Australia, then follow the venue guidance and keep documentation ready for scientific and award applications.